Gracell Biotechnologies Inc. (GRCL)

NASDAQ
4.99
-0.42(-7.76%)
After Hours
4.92
-0.07(-1.40%)
- Real-time Data
  • Volume:
    118,693
  • Day's Range:
    4.85 - 5.43
  • 52 wk Range:
    1.68 - 15.00

GRCL Overview

Prev. Close
5.41
Day's Range
4.85-5.43
Revenue
370K
Open
5.42
52 wk Range
1.68-15
EPS
-0.97
Volume
118,693
Market Cap
337.35M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
153,972
P/E Ratio
-
Beta
-
1-Year Change
-63.71%
Shares Outstanding
67,604,671
Next Earnings Date
Aug 16, 2022
What is your sentiment on Gracell Biotechnologies?
or
Market is currently closed. Voting is open during market hours.

Gracell Biotechnologies Inc. Company Profile

Gracell Biotechnologies Inc. Company Profile

Employees
348

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin’s lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company’s product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellNeutralBuySell
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Sell
SummaryStrong SellStrong SellSellStrong BuyStrong Sell